Creating therapeutic Disulfide-Rich Peptides targeting transmembrane proteins including ion channels, GPCRs, and transporters. | Veneno Technologies is a Japan-origin deep-tech biotech company founded in 2020 and built around a proprietary Disulfide-Rich Peptide, or DRP, discovery platform. Based on scientific achievements originating from AIST, the company has established an integrated end-to-end system combining design, screening, functional evaluation, and production of DRPs through its proprietary Veneno Suite and PERISS platform. Veneno aims to create a new peptide modality for targets that have remained difficult to address with conventional small molecules or antibodies. The company’s core strength lies in its ability to translate the intrinsic biological advantages of naturally occurring DRPs into an industrial discovery engine. Because DRPs possess multiple disulfide bonds and a conformationally constrained structure, they can offer high stability, protease resistance, thermal robustness, and strong target selectivity. These properties make DRPs especially attractive for membrane proteins and other challenging target classes where conventional modalities often face limitations in selectivity, penetration, or functional control. Veneno is leveraging this differentiated biology to generate novel therapeutic candidates with the potential to open new mechanisms of action in previously hard-to-drug disease areas. Current Strategic Focus Areas 1) Ri-DRP drug discovery: Veneno is actively advancing Ri-DRP programs in which DRPs are conjugated with radioactive payloads, including alpha-emitting isotopes. By combining the high target selectivity and compact size of DRPs with radiopharmaceutical design, the company aims to enable precise tumor targeting and differentiated payload delivery beyond what is often achievable with conventional antibody-based radioconjugates or small-molecule radiopharmaceuticals. Ri-DRP represents a highly strategic direction for Veneno, particularly in oncology, where target-specific delivery, tissue distribution, and therapeutic precision are central to next-generation drug design. 2) Functional development of DRPs as next-generation antibody-like molecules: Veneno positions DRPs not simply as peptides, but as a next-generation functional modality that can complement and, in selected settings, outperform antibodies. The compact and highly structured nature of DRPs allows precise interaction with biologically important surfaces while maintaining strong stability and selectivity. This creates opportunities in areas where antibodies may be constrained by tissue penetration, epitope accessibility, or molecular size. Veneno is therefore developing DRPs as next-generation antibody-like agents for membrane proteins, complex interaction interfaces, and disease areas that require finely tuned molecular recognition. 3) DRP drug discovery for membrane proteins including ion channels, GPCRs, and transporters: Veneno’s discovery platform is particularly differentiated in the generation of functional DRPs against membrane proteins that have historically been difficult to drug. Through the proprietary PERISS method, the company can identify inhibitor, activator, and binder DRPs for ion channels, GPCRs, transporters, and related membrane targets. These target classes are biologically important across oncology, inflammation, pain, cardiometabolic disorders, and other major therapeutic areas, yet they remain challenging because small molecules can suffer from off-target effects and antibodies often have limited access to the relevant target surfaces. Veneno is using DRPs to bridge this gap and unlock first-in-class opportunities in membrane protein drug discovery. Through these three focus areas, Veneno Technologies is positioning DRPs as a scalable platform for next-generation therapeutics spanning membrane protein drug discovery, antibody-like functional molecules, and radiopharmaceutical innovation. At BIO International 2026, the company is seeking global collaboration opportunities including joint research, co-development, licensing, and strategic partnerships with pharmaceutical companies, biotech innovators, radiopharmaceutical developers, and research institutions.
Vacino Biotech Co., Ltd.
Vacino Biotech focuses on innovations for HLA-peptide based vaccine (9-mer peptide), nucleic acid medicine (microRNA) and brain delivery technology (targeting peptide) for the indication of infectious disease, neurodegenerative disease and oncology. Core products: Oral universal COVID vaccine against SARS-CoV-2 variants A microRNA-based anti-neuroinflammation therapeutics A brain shuttled anti-Her2 antibody for treating the peripheral and intracranial tumors. An oral bioavailable brain-targeting LNP for delivering the oligonucleotide and large molecule therapeutics Show less Description (NOTE: Given time constraints & strategic priorities, we will not be meeting with CMOs, CROs, service companies, etc. at the meeting) Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer’s disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage. ● Core products and platform technology Oral universal COVID-19 vaccine: VACINO-CO is a novel oral universal antigen vaccine designed to protect against most COVID-19 viruses and related variants. Through the activation of T cells, it can eliminate virus-infected cells, which can effectively inhibit recurrence and the phenomenon of seroconversion. The innovative and convenient oral dosage form can be applied to the elderly and children in vulnerable groups to obtain safer and effective immunity, safe and effective immune protection of the population. It is currently about to enter human clinical trials. MicroRNA-based Alzheimer’s Disease Drug Developments: Patented Vacino-ADmir is a microRNA-based drug that inhibits neuroinflammation through the PD1/PDL1 mechanism associated with inflammation and can be treated from the source of the disease, which is different from the symptomatic treatment on the market. It can be applied to dementia and neuroinflammation-related diseases. GMP manufacturing is currently underway. High-Performance Brain Delivery Platform Technology: The patented Vacino-BT target peptide can be co-transported by binding to transferrin receptors through transcytosis, with a brain delivery rate of more than 20 % a 1-hour post-injection, which is far superior to other brain delivery technologies on the market. At present, it has been successfully applied to antibodies and lipid nanoparticles. GoBrain LNP: Based VBT technology, we developed VBT-lipid conjugates that can enable LNP having brain targeting capability. HerBrain and eHerbrain platform: Based on VBT technology, we developed chemically modified anti-Her2 antibody and novel DNA-engineered anti-Her2 antibody, which allows brain shuttle capability and tissue penetration.
Turbine
Turbine is virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays. Running experiments at computational speed and scale allows researchers to test millions of ideas, beyond physical lab constraints, to understand biological drivers of disease. Working with scientists at leading biopharma like MSD (Merck & Co.), AstraZeneca and Bayer, Turbine’s virtual assays have rationalized experiments across more than 30 discovery programs. Backed by leading tech and industry investors like Accel, MSD Global Health Innovation Fund, Interactive Venture Partners and Beiersdorf, Turbine is turning biology into an engineering discipline.
Taiwan Universe BioMedicine
Innovative platform of enterovirus and influenza VLP vaccines. – Promising option to combat viruses mutation – Provide a broad-spectrum prevention with better immunogenicity – Enable faster scaling-up
Suven Life Sciences Limited
Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer’s disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson’s disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer’s type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.
Simpson Biotech Co., Ltd.
Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag. New product launched in 2023: 1. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation, 2. Potent anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; 2. World’s first high purity (chitobiose+chitotriose > 90%) oligo chitosan for weight, diabetes and triglyceride control; 3. Hydrolyzed Fucoidan for immune & glucose control. SBC has won numerous awards with 54 patents issued. —–>—– 【Natural Compound as Oral Drug development for NAFLD/NASH】 Reduce liver triglyceride and cholesterol in NAFLD Reduce serum triglyceride and cholesterol in NAFLD Reduce liver fat deposition in NAFLD Reduce ALT and AST in NAFLD Anti-inflammation and oxidative stress Anti-fibrosis US, CN, TW patents granted 【Recombinant Protein Expression/Purification Platform (HERPEPSTM) and Products】 Patent Recombinant Protein Platform & CDMO Service – Cost-effective recombinant protein expression & purification system; From gene to protein Starch Binding Protein (SBP) as an affinity tag One-step purification of recombinant protein by starch Protein immobilization on starch enhanced the thermostability & shelf life Easy to scale up: From 100L lab-scale concept proof to 8000L mass production Ideal for industrial, food, feed enzymes Self-owned Tool Box for Protein Expression in Pichia pastoris Methanol-induced or Methanol-free expression Antibiotics-free expression host Genetic manipulation of expression strain with high yield Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical studies. One clinical study for Rheumatoid Arthritis (RA) has been completed. Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 Alcoholic Hangover Release : Antrodia cinnamomea mycelia Neuroprotective & Memory Enhancement : Ginsenoside compound K Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia Heart Protection : Agaricus blazei murill Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts Fermented Vegetables & Grains Concentrate as prebiotics Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. IFN-γ Stimulant Anti-viral Antibiotic alternative Anti-coccidia Increase feed efficiency US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. (SBC), a private Co. founded in 1998, located in Taiwan is focusing on: (I). Medicinal fungus fermentation & enzymatically hydrolyzed bioactive natural ingredients used for dietary supplements, cosmetics & drug discovery. (II). OEM/ODM services for Recombinant Proteins (i.e. Industrial Enzymes), using a patented starch-binding protein as the affinity tag and in-house non-methanol, antibiotics-free expression strain. Highlight in 2024: 1. Recombinant protein OEM/ODM with proprietary yeast platform, 2. Antrodia cinnamomea extract as natural ingredient for cosmetics formulation. 3. Antrodin as potent oral drug for NAFLD/NASH; 4. Natural anti-yeast & anti-bacteria soluble chitosan for food/drug & agriculture applications; SBC has won numerous awards with 54 patents issued. —–>—– 【Recombinant Protein OEM/ODM with Proprietary Yeast Platform】 – One-step purification of recombinant protein by starch – Protein immobilization on starch enhanced the thermostability & shelf life – Easy to scale up: From 100L lab-scale concept proof to 8000L mass production – Ideal for industrial, food, feed enzymes – Turn-key licensed(non-exclusive) to global feed company already > – In-house Non-Methanol promoter compared to AOX1 – Antibiotics-free expression strain: Eco-friendly – Genetic manipulation of expression strain with high yield – Cost can be 12%) of Simpson Biotech’s currently marketed dietary supplement actually illustrates both the safety and the effectiveness of the mycelia and the compound of Hepasim® through human clinical study for Rheumatoid Arthritis (RA). – Initial results from the clinical study plus the previous metabolic/pharmacokinetic animal studies on these compounds already illustrate that Hepasim® is a promising NCE drug candidate. 【Fermented natural products for dietary supplement】 – Alcoholic Hangover Release : Antrodia cinnamomea mycelia – Neuroprotective & Memory Enhancement : Ginsenoside compound K – Immune Regulation : Cordyceps sinensis mycelia, Hydrolyzed Fucoidan – Male Hormone (Testosterone) Stimulant : Cordyceps sinensis mycelia – Heart Protection : Agaricus blazei murill – Increase Stamina : low molecular weight functional peptides from casein, whey, soy, collagen, silk – OEM/ODM Fermentation : Cordyceps sinensis, Phellinus linteus, Ganoderma lucidum, Agaricus blazei murill and other mycelia and their extracts – Fermented Vegetables & Grains Concentrate as prebiotics – Cosmetics for skin whitening & anti-scar : Antrodia cinnamomea extract 【Immune booster for IFN-γ stimulation as anti-viral and antibiotic alternative feed additive】 LZ-8 is a fungal immunomodulatory protein originally isolated from the popular oriental medicinal fungus. Oral administration of rLZ-8 stimulates IFN-γ secretion. It is not only a good dietary supplement for humans but also an antibiotic alternative for animal additives for the prevention of virus or coccidia infection in field studies. Possible pharmaceutical applications per oral include immune-regulatory diseases. – IFN-γ Stimulant – Anti-viral – Antibiotic alternative – Anti-coccidia – Increase feed efficiency – US, TW, CN patent granted (US9950028, I589586, CN106232133A) | Simpson Biotech Co., Ltd. specializes in bio-fermentation development and commercialization: 1. Medicinal fungi for dietary supplements and early-stage drug discovery, specifically Hepasim®. 2. SimpsonPure health supplements portfolios. 3. Patented platform developing for recombinant protein expression and purification. We are seeking partnerships for the development of new recombinant proteins.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.